Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose pulsatile Erlotinib or Gefitinib in advanced NSCLC
NCT01965275Phase 2Unknown
- Sponsor
- Anhui Medical University
- Start
- Oct 2013
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, gefitinib in non-small cell lung cancer (NSCLC), sponsored by Anhui Medical University. Status: unknown.
02
Drugs
erlotinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01965275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965275.